A retrospective analysis of clinicopathologic data and survival outcomes from 355 patients diagnosed with DLBCL demonstrated that a CD163+ M2 TAM content of 9.5% or greater negatively affects the prognosis of DLBCL [151]. This evidence concerns the gene CD163 and diffuse large B-cell lymphoma.